Investor Relations

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 22, 2024-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences:

• Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44^th Annual Health Care Conference on Tuesday, March 5 in Boston, MA; fireside chat at 11:10 a.m. Eastern Time.
• Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the Barclays 26^th Annual Global Healthcare Conference on Tuesday, March 12 in Miami, FL; fireside chat at 7:30 a.m. Eastern Time.

The fireside chats will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222694551/en/

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Source: Twist Bioscience Corporation